Slovenian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
maytansine/rak
Povezava se shrani v odložišče
Stran 1 iz 82 rezultatov
Tubulin Maytansine Site Binding Ligands and Their Applications as MTAs and ADCs for Cancer Therapy.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Metabolism studies of the anti-tumor agent maytansine and its analog ansamitocin P-3 using liquid chromatography/tandem mass spectrometry.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Maytansine, a potent clinically evaluated plant-derived anti-tumor drug, and its microbial counterpart, ansamitocin P-3, showed a substantially higher cytoxicity than many other anti-tumor drugs. Owing to a shortage of material and lack of sufficiently sensitive analytical methods at the time, no
Minimal single-agent activity of maytansine in refractory breast cancer: a Southwest Oncology Group study.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Maytansine is an experimental antitumor agent that has shown minimal efficacy against breast cancer with minimal myelosuppression in phase I trials. Forty-one patients with advanced drug-resistant breast cancer were treated with a 5-day intermittent iv infusion of maytansine repeated every 21 days.
Phase II trials of maytansine, low-dose chlorozotocin, and high-dose chlorozotocin as single agents against advanced measurable adenocarcinoma of the pancreas. Gastrointestinal Tumor Study Group.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
One hundred and five patients with advanced measurable pancreatic carcinoma were randomized to receive therapy with maytansine, low-dose chlorozotocin (120 mg/m2), or high-dose chlorozotocin (175 mg/m2). Objective response rates were as follows: maytansine, no responses among 48 patients; low-dose
Semisynthetic maytansine analogues for the targeted treatment of cancer.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Maytansine, a highly cytotoxic natural product, failed as an anticancer agent in human clinical trials because of unacceptable systemic toxicity. The potent cell killing ability of maytansine can be used in a targeted delivery approach for the selective destruction of cancer cells. A series of new
Zein nanoparticles as nontoxic delivery system for maytansine in the treatment of non-small cell lung cancer.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Purpose: Maytansine (DM1) is a potent anticancer drug and limited in clinical application due to its poor water solubility and toxic side effects. Zein is widely used in nano drug delivery systems due to its good biocompatibility. In this study, we prepared DM1-loaded zein nanoparticles
Aptamer Enables Consistent Maytansine Delivery Through Maintaining Receptor Homeostasis for HER2 Targeted Cancer Therapy
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Although the extensive clinical use of the ADC trastuzumab-DM1(T-DM1) for human epidermal growth factor receptor 2 (HER2) targeted cancer therapy, many patients who initially respond to T-DM1 treatment eventually met the insufficient efficacy issue, which is partly attributed to the decreased amount
Antibody-DM1 conjugates as cancer therapeutics.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Synthetic derivatives of the microtubule-targeted agent maytansine, commonly known as drug maytansinoids or DMs, are emerging as potential cancer therapeutics. DM1 is an antibody-conjugatable maytansinoid that was developed to overcome systemic toxicity associated with maytansine and to enhance
Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Trastuzumab emtansine (Kadcyla®), an antibody-drug conjugate of trastuzumab (Herceptin®) connected by a thioether linker to the microtubule inhibitor DM1 (a cytotoxic derivative of maytansine), provides direct intracellular delivery of the potent cytotoxin DM1 to
Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
BACKGROUND
Ado- trastuzumab emtansine (T-DM1) is a human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate composed of trastuzumab, a stable linker (MCC), and the cytotoxic agent DM1 (derivative of maytansine; mertansine). T-DM1 retains the mechanisms of action of
Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
The human epidermal growth factor receptor 2 (HER2) is overexpressed in 20% of breast carcinomas. Prior to the development of targeted therapies, HER2-positive breast cancer was associated with more aggressive disease and poor prognosis. Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate
A fluorescence anisotropy assay to discover and characterize ligands targeting the maytansine site of tubulin.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Microtubule-targeting agents (MTAs) like taxol and vinblastine are among the most successful chemotherapeutic drugs against cancer. Here, we describe a fluorescence anisotropy-based assay that specifically probes for ligands targeting the recently discovered maytansine site of tubulin. Using this
Trastuzumab emtansine in breast cancer.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
BACKGROUND
Trastuzumab emtansine (T-DM1) is a human epidermal growth factor receptor 2 (HER2)-targeted antibody-drug conjugate (ADC) composed of trastuzumab, a stable linker (MCC), and the cytotoxic agent DM1 (derivative of maytansine). Administration of T-DM1 leads to limited systemic exposure of
Aptamer-Drug Conjugates of Active Metabolites of Nucleoside Analogs and Cytotoxic Agents Inhibit Pancreatic Tumor Cell Growth.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Aptamer-drug conjugates (ApDCs) have the potential to improve the therapeutic index of traditional chemotherapeutic agents due to their ability to deliver cytotoxic drugs specifically to cancer cells while sparing normal cells. This study reports on the conjugation of cytotoxic drugs to an aptamer
Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer.
Samo registrirani uporabniki lahko prevajajo članke
Prijava / prijava
Trastuzumab emtansine (T-DM1) is a human epidermal growth factor receptor (HER2)-targeted antibody-drug conjugate, composed of trastuzumab, a stable thioether linker, and the potent cytotoxic agent DM1 (derivative of maytansine), in phase III development for HER2-positive cancer. Extensive analysis
Najbolj popolna baza zdravilnih zelišč, podprta z znanostjo
- Deluje v 55 jezikih
- Zeliščna zdravila, podprta z znanostjo
- Prepoznavanje zelišč po sliki
- Interaktivni GPS zemljevid - označite zelišča na lokaciji (kmalu)
- Preberite znanstvene publikacije, povezane z vašim iskanjem
- Iščite zdravilna zelišča po njihovih učinkih
- Organizirajte svoje interese in bodite na tekočem z raziskavami novic, kliničnimi preskušanji in patenti
Vnesite simptom ali bolezen in preberite o zeliščih, ki bi lahko pomagala, vnesite zelišče in si oglejte bolezni in simptome, proti katerim se uporablja.
* Vse informacije temeljijo na objavljenih znanstvenih raziskavah
